DXNVX Partners with JinScript for New Drug Development
DXVX has taken its first step toward global clinical trials by accelerating new drug development through collaboration with a global bio company.
On the 13th, DXVX announced that it signed a strategic partnership (MOU) with Jinscript ProBio, a global CDMO company, for the development of anticancer antibody new drugs.
The partnership signing ceremony held at DXVX’s headquarters in Gasan-dong was attended by DXVX CTO Han Sung-jun, Evixgen Vice President Kim Byung-jin, and Felix Zhu, Vice President and Head of the Antibody Division at Jinscript ProBio. DXVX expects to secure additional pipelines through this strategic partnership.
Jinscript ProBio is a global subsidiary of Jinscript, a global bio CRO and CDMO company. The company is expected to create significant synergy in the future as it provides one-stop services from drug development to commercialization through specialized solutions and efficient processes related to antibody drugs and cell and gene therapies.
Through this strategic partnership, DXVX plans to accelerate the development of its own anticancer antibody new drugs. In particular, based on the global human antibody library owned by Jinscript ProBio, early-stage development for clinical entry?including lead discovery for anticancer antibody new drugs, cell line development, manufacturing quality control (CMC), and production of non-clinical samples?will be carried out.
The anticancer antibody new drug development with Jinscript ProBio will proceed using the research personnel of DXVX and its subsidiary Evixgen, as well as the global network of the Kori Group for clinical trials and development.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- Instead of a National Assembly Profile, Now a 'Carpenter'... Ryu Hojung Says "I Couldn't Do a Body Profile Shoot Twice"
Han Sung-jun, CTO of DXVX, emphasized, “We expect to accelerate our own new drug development projects and increase the likelihood of success through collaboration with Jinscript ProBio, which has participated in the development of drugs for numerous global pharmaceutical companies,” adding, “We will continue to expand cooperation with global pharmaceutical and bio companies aiming for global clinical trials in the future.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
